Carlos M
@carlosmmed.bsky.social
Medicina Interna.
Autoinmunes.
Madrid. España.
Autoinmunes.
Madrid. España.
Obinituzumab in NL in NEJM 2025.
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...
www.nejm.org
February 8, 2025 at 6:31 PM
Obinituzumab in NL in NEJM 2025.
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....
But… complete renal response 30.9% in the placebo group?
www.nejm.org/doi/full/10....